Donepezil Hydrochloride Rosemont Pharmaceutical (Donepezil Hydrochloride)

Donepezil Hydrochloride Rosemont Pharmaceutical is indicated for the symptomatic treatment of cognitive decline associated with certain neurodegenerative conditions.

• Mild to moderate Alzheimer’s disease, as approved in the EU.
• Dementia related to Parkinson’s disease, when prescribed by a neurologist.
• Cognitive impairment in Lewy body dementia, as part of a comprehensive care plan.
• Off‑label use in vascular dementia may be considered by clinicians based on individual assessment.

The safety profile of donepezil includes a range of adverse events that are categorized by frequency and severity.

Common

• Nausea or upset stomach.
• Diarrhea or loose stools.
• Insomnia or abnormal dreams.
• Muscle cramps or fatigue.
• Loss of appetite.

Serious

• Severe bradycardia or heart block.
• Gastrointestinal bleeding.
• Hepatotoxicity indicated by elevated liver enzymes.
• Seizures in predisposed individuals.
• Allergic reactions such as rash, angioedema, or anaphylaxis.

Clinicians should evaluate several precautionary factors before initiating therapy with Donepezil Hydrochloride Rosemont Pharmaceutical.

• Cardiac conduction disorders, including sick sinus syndrome.
• History of asthma or chronic obstructive pulmonary disease.
• Active peptic ulcer disease or gastrointestinal bleeding risk.
• Severe liver impairment (Child‑Pugh C).
• Concomitant use of other cholinesterase inhibitors.
• Renal impairment may require dose adjustment.

Donepezil may interact with other medicines, influencing its efficacy or safety profile.

Avoid

• Strong CYP3A4 or CYP2D6 inhibitors (e.g., ketoconazole, ritonavir).
• Anticholinergic agents that counteract its mechanism (e.g., atropine, scopolamine).

Use with caution

• Anticoagulants or antiplatelet drugs due to bleeding risk.
• Beta‑blockers or other bradycardia‑inducing agents.
• CNS depressants that may increase dizziness.
• NSAIDs or steroids that may exacerbate gastrointestinal side effects.